149 related articles for article (PubMed ID: 11894635)
1. Unknown primary detected by FDG-PET. A review of the present indications of FDG-PET in head and neck cancers.
Sheikholeslam-zadeh R; Choufani G; Goldman S; Hassid S
Acta Otorhinolaryngol Belg; 2002; 56(1):77-82. PubMed ID: 11894635
[TBL] [Abstract][Full Text] [Related]
2. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
AAssar OS; Fischbein NJ; Caputo GR; Kaplan MJ; Price DC; Singer MI; Dillon WP; Hawkins RA
Radiology; 1999 Jan; 210(1):177-81. PubMed ID: 9885604
[TBL] [Abstract][Full Text] [Related]
3. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study.
Johansen J; Eigtved A; Buchwald C; Theilgaard SA; Hansen HS
Laryngoscope; 2002 Nov; 112(11):2009-14. PubMed ID: 12439171
[TBL] [Abstract][Full Text] [Related]
4. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
[TBL] [Abstract][Full Text] [Related]
5. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
[TBL] [Abstract][Full Text] [Related]
6. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.
Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT
Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570
[TBL] [Abstract][Full Text] [Related]
7. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.
Yao M; Graham MM; Hoffman HT; Smith RB; Funk GF; Graham SM; Dornfeld KJ; Skwarchuk M; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1001-10. PubMed ID: 15234033
[TBL] [Abstract][Full Text] [Related]
8. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.
Farber LA; Benard F; Machtay M; Smith RJ; Weber RS; Weinstein GS; Chalian AA; Alavi A; Rosenthal DI
Laryngoscope; 1999 Jun; 109(6):970-5. PubMed ID: 10369292
[TBL] [Abstract][Full Text] [Related]
9. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients.
Paulus P; Sambon A; Vivegnis D; Hustinx R; Moreau P; Collignon J; Deneufbourg JM; Rigo P
Laryngoscope; 1998 Oct; 108(10):1578-83. PubMed ID: 9778305
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
11. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography.
Stoeckli SJ; Mosna-Firlejczyk K; Goerres GW
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):411-6. PubMed ID: 12634970
[TBL] [Abstract][Full Text] [Related]
12. [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region].
Bohuslavizki KH; Klutmann S; Sonnemann U; Thoms J; Kröger S; Werner JA; Mester J; Clausen M
Laryngorhinootologie; 1999 Aug; 78(8):445-9. PubMed ID: 10488465
[TBL] [Abstract][Full Text] [Related]
13. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomography in occult primary head and neck cancers.
Safa AA; Tran LM; Rege S; Brown CV; Mandelkern MA; Wang MB; Sadeghi A; Juillard G
Cancer J Sci Am; 1999; 5(4):214-8. PubMed ID: 10439166
[TBL] [Abstract][Full Text] [Related]
15. Can positron emission tomography improve the quality of care for head-and-neck cancer patients?
Schechter NR; Gillenwater AM; Byers RM; Garden AS; Morrison WH; Nguyen LN; Podoloff DA; Ang KK
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):4-9. PubMed ID: 11516844
[TBL] [Abstract][Full Text] [Related]
16. Positron emission imaging of head and neck cancer, including thyroid carcinoma.
Schöder H; Yeung HW
Semin Nucl Med; 2004 Jul; 34(3):180-97. PubMed ID: 15202100
[TBL] [Abstract][Full Text] [Related]
17. [Positron emission tomography in head and neck oncology: five cases].
Courtois A; Foehrenbach H; Maszelin P; De Dreuille O; Garcia D; Kossowski M; Merlet P; Gaillard JF; Poncet JL
Ann Otolaryngol Chir Cervicofac; 2001 Sep; 118(4):254-60. PubMed ID: 11679846
[TBL] [Abstract][Full Text] [Related]
18. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment.
Yao M; Luo P; Hoffman HT; Chang K; Graham MM; Menda Y; Tan H; Buatti JM
Am J Clin Oncol; 2007 Jun; 30(3):264-70. PubMed ID: 17551303
[TBL] [Abstract][Full Text] [Related]
19. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of positron emission tomography (PET) with (18F)fluorodeoxyglucose (FDG) in head and neck tumours.
Ekberg T; Sörensen J; Engström M; Blomquist E; Sundin A; Anniko M
Acta Otolaryngol; 2007 Feb; 127(2):186-93. PubMed ID: 17364351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
